Functional Dyspepsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Functional Dyspepsia Market Outlook

Thelansis’s “Functional Dyspepsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Functional Dyspepsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Functional Dyspepsia Overview

Functional dyspepsia, a chronic disorder affecting sensation and peristalsis in the upper digestive tract, entails abnormal movement in the esophagus, stomach, and small intestine after swallowing. It is more prevalent among women, owing to inherent gender-specific differences in gastrointestinal function. The disrupted motility in functional dyspepsia leads to heightened sensations in the upper gut (visceral hyperalgesia). This results from disorganized and often ineffective emptying of the upper digestive tract, resulting in pain, fullness, bloating, and difficulty finishing meals. Common accompanying symptoms include heartburn, a sour taste in the mouth, excessive burping, nausea, and occasional vomiting. Understanding the exact mechanism behind functional dyspepsia remains elusive, as its pathophysiology is intricate. Various mechanisms are believed to contribute to each subtype. Traditionally, disturbances in gastric physiological factors have been divided into macroscopic and microscopic mechanisms.

Macroscopic mechanisms encompass

• Gastroesophageal reflux (GERD)
• Delayed gastric emptying, rapid gastric emptying, gastric dysrhythmias, and antral hypomotility
• Visceral hypersensitivity with nervous system alterations

Microscopic mechanisms encompass

• Impaired barrier function
• Gastroduodenal inflammation
• Altered gut microbiome and Helicobacter pylori infection

Two primary medication-based approaches to treating functional dyspepsia involve neutralizing acid and inhibiting its production. Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are two drugs that reduce acid secretion. It's crucial to consider conditions like GERD, H. pylori infection, gastritis, peptic ulcer disease, and celiac disease as potential differential diagnoses. Functional dyspepsia, the leading cause of dyspeptic symptoms, accounts for 8 out of 10 cases of indigestion.

• Globally, approximately 7 in every 100 individuals suffer from functional dyspepsia, with a slightly higher prevalence in adults aged 18 to 39 compared to older age groups.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: